The Drug-Induced Respiratory Disease Website
Philippe Camus, M.D.
Browse by »
Pleural thickening/fibrosis - Fibrothorax
Last update :
Drug and radiation history
Drug singularity - Correct identification of the drug
Consistent timing of exposure v. onset of symptoms
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
Careful exlusion of another cause
Remission of symptoms with removal of drug
Recurrence with rechallenge (rarely advisable)
More detailed checklist
See also under
Ergots, ergot alkaloids, ergolines
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
Fibrosis associated with dopamine agonist therapy in Parkinson's disease.
Chronic constrictive pericarditis induced by long-term bromocriptine therapy: report of two cases.
Pleuropulmonary disease as a side-effect of treatment with bromocriptine.
Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos.
Bromocriptine and pleuropulmonary disease.
Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease.
Pleuropulmonary involvement during bromocriptine treatment.
Pleuropulmonary reactions in patients on bromocriptine treatment.
[Pleuropulmonary fibrosis and bromocriptine].
Pleuropulmonary shadows on bromocriptine.